My cart
In the shopping cart is not goods, to choose and buy!
  • Product Name
  • Size
  • Quantity
  • Amount
    Selected items : 0 pieces Total : CHECK OUT()
    Duvelisib (IPI-145, INK1197)
    Duvelisib (IPI-145, INK1197)

    Market Price:

    This product is for research use only, not for human use. We do not sell to patients.
    Number: - + Pieces(InventoryPieces)
    InvivoChem Cat #: V0127
    CAS #: 1201438-56-3Purity ≥98%

    Description:Duvelisib (formerly known as IPI-145 and INK1197, trade name: Copiktra),  an isoquinolinone derivative, is a novel potent, orally bioactive and selective small-molecule phosphoinositide-3 kinases (PI3K) inhibitor with potential anticancer activity. It selectively and potently inhibits two PI3K isoforms, PI3K-δ and PI3K-γ, with IC50 of 2.5 nM and 27 nM respectively. In 2018, Duvelisib was approved by FDA to treat relapsed or refractory chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL) and follicular lymphoma.  

    References: Chem Biol. 2013 Nov 21;20(11):1364-74;  2016 Jun 28;7(26):39784-39795. 

    Related CAS: 1261590-48-0 (R-isomer); 1386861-49-9 (hydrate) 

    Customer Validation
    Official Supplier of
    • VE
    • OF
    • YALE
    • hhmi
    • 香港大学
    Publications Citing InvivoChem Products
    • Physicochemical and Storage Information
    • Protocol
    • Quality Control Documentation
    • Related Biological Data
    • Customer Review

    Molecular Weight (MW)




    CAS No.



    -20℃ for 3 years in powder form

    -80℃ for 2 years in solvent

    Solubility (In vitro)

    DMSO: 83 mg/mL (199.1 mM)

    Water:<1 mg/mL

    Ethanol: <1 mg/mL

    Solubility (In vivo)

    30% PEG400+0.5% Tween80+5% Propylene glycol: 30mg/mL

    Chemical Name



    IPI145; IPI 145; IPI-145. INK1197; INK 1197; INK-1197; trade name: Copiktra

    Other info

    Chemical Name: (S)-3-(1-((9H-purin-6-yl)amino)ethyl)-8-chloro-2-phenylisoquinolin-1(2H)-one


    InChi Code: InChI=1S/C22H17ClN6O/c1-13(28-21-19-20(25-11-24-19)26-12-27-21)17-10-14-6-5-9-16(23)18(14)22(30)29(17)15-7-3-2-4-8-15/h2-13H,1H3,(H2,24,25,26,27,28)/t13-/m0/s1

    SMILES Code: O=C1N(C2=CC=CC=C2)C([[email protected]@H](NC3=C4N=CNC4=NC=N3)C)=CC5=C1C(Cl)=CC=C5


    • Molarity Calculator
    • Dilution Calculator
    • The molarity calculator equation

      Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

      • Mass
      • Concentration
      • Volume
      • Molecular Weight *
      • =
      • ×
      • ×
    • The dilution calculator equation

      Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

      This equation is commonly abbreviated as: C1V1 = C2V2

      • Concentration (start)
      • ×
      • Volume (start)
      • =
      • Concentration (final)
      • ×
      • Volume (final)
      • ×
      • =
      • ×
      • C1
      • V1
      • C2
      • V2

    In Vitro

    In Vitro Assay: Duvelisib is a selectivite p100δ inhibitor with IC50 of 2.5 nM, 27.4 nM, 85 nM and 1602 nM for p110δ, P110γ, p110β and p110α, respectively. PI3Kδ and PI3Kγ inhibition with IPI-145 has anti-proliferative activity in primary AML cells by inhibiting the activity of AKT and MAPK. Pre-treatment of AML cells with IPI-145 inhibits both adhesion and migration of AML blasts to bone marrow stromal cells

    Cell Assay: IPI-145 suppresses murine/human B-cell proliferation with EC50 of 0.5 nM/0.5 nM and also inhibits human T-cell proliferation with EC50 of 9.5 nM.

    In Vivo

    IPI-145 (10 mg/kg, p.o.) shows well pharmacokinetics with Cmax and AUC of 390 ng/mL and 137 ng•h/mL in mouse and rat. IPI-145 (10 mg/kg) is active in murine DTH model with ~50% ear swelling. IPI-145 (10 mg/kg) demonstrates dose-dependent effect in rat collagen induced arthritis (CIA) model. IPI-145 prevents inflammation and protects joint bone and cartilage in the rat CIA model. IPI-145 (10 mg/kg,QD) demonstrates activity in rat adjuvant induced polyarthritis model.

    Animal model

     Mouse and rat with collagen induced arthritis (CIA) model.

    Formulation & Dosage

     10 mg/kg, p.o.


    Chem Biol. 2013 Nov 21;20(11):1364-74.  

    These protocols are for reference only. InvivoChem does not independently validate these methods.

    Duvelisib (IPI-145, INK1197)

    Duvelisib (IPI-145, INK1197)
    Duvelisib (IPI-145, INK1197)

    Targeting PI3K inhibits AML survival in AML cell lines and primary AML blasts. 

    IPI-145 inhibits AKT phosphorylation in AML.  2016 Jun 28;7(26):39784-39795.

    IPI-145 inhibits adhesion of AML blasts to primary BMSC.  2016 Jun 28;7(26):39784-39795.


      Home Prev Next Last page / pices


      Your information is safe with us. * Required Fields.
      Products are for research use only;  We do not sell to patients
      Tel: 1-708-310-1919
      Fax: 1-708-557-7486
      Subscribe to our E-newsletter
      • Name*
      • *
      • E-mail*
      • *
      • instructions:
      • *
      Copyright 2020 InvivoChem LLC | All Rights Reserved
      Do you confirm the receipt?